Drug Profile
Research programme: transdermal influenza vaccine - Corium International
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Corium International; Novartis Vaccines
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in USA (Transdermal)
- 17 Dec 2018 Corium International has been acquired by Gurnet point capital
- 18 May 2015 Preclinical trials in Influenza virus infections (Prevention) in USA (Transdermal)